UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)
0.8594 x 15 0.9115 x 4
Pre-market by (Cboe BZX)
0.8900 +0.0100 (+1.14%) 04/22/25 [NASDAQ]
0.8594 x 15 0.9115 x 4
Pre-market 0.8900 unch (unch) 15:54 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.8800
Day High
0.9180
Open 0.9000
Previous Close 0.8800 0.8800
Volume 48,500 48,500
Avg Vol 63,505 63,505
Stochastic %K 19.61% 19.61%
Weighted Alpha -45.87 -45.87
5-Day Change +0.0038 (+0.43%) +0.0038 (+0.43%)
52-Week Range 0.8101 - 1.8400 0.8101 - 1.8400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,837
  • Shares Outstanding, K 21,406
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,010 K
  • EBIT $ -16 M
  • EBITDA $ -15 M
  • 60-Month Beta 0.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.78
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.73
  • Most Recent Earnings $-0.23 on 03/31/25
  • Next Earnings Date 06/13/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8400 +5.95%
on 04/16/25
Period Open: 1.0450
1.1329 -21.44%
on 03/24/25
-0.1550 (-14.83%)
since 03/21/25
3-Month
0.8400 +5.95%
on 04/16/25
Period Open: 1.1900
1.2900 -31.01%
on 03/14/25
-0.3000 (-25.21%)
since 01/22/25
52-Week
0.8101 +9.86%
on 11/21/24
Period Open: 1.2700
1.8400 -51.63%
on 04/29/24
-0.3800 (-29.92%)
since 04/22/24

Most Recent Stories

More News
RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis

Unlock AI-powered insights for data-driven precision and real-time efficiency

ENLV : 0.8900 (+1.14%)
ASPI : 5.53 (+2.03%)
BFRG : 1.6700 (+0.60%)
NVA : 12.64 (-5.18%)
GRRR : 17.42 (+2.83%)
The Trump Effect: Crypto Diversification Accelerates Across Industries

Issued on behalf of Spearmint Resources Inc. VANCOUVER – USA News Group – With the upcoming inauguration of US President Re-Elect Donald Trump on the horizon, several businesses are diversifying...

MSTR : 343.03 (+7.95%)
TSLA : 237.97 (+4.60%)
ENLV : 0.8900 (+1.14%)
SPMTF : 0.0103 (-16.94%)
SPMT.CN : 0.0150 (unch)
^BTCUSDT : 94,294.98 (+3.49%)
HOTH : 0.8000 (+3.69%)
^BTCUSD : 94,239.84 (+3.40%)
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks,...

ENLV : 0.8900 (+1.14%)
BIAF : 0.5100 (+2.70%)
Enlivex Therapeutics Ltd. Receives Approval for Phase I Trial of Allocetra™ in TMJ Osteoarthritis Patients

Enlivex Therapeutics received authorization for a Phase I trial of Allocetra™ for TMJ osteoarthritis in Israel.Quiver AI SummaryEnlivex Therapeutics Ltd. has received approval from the Israeli Ministry...

ENLV : 0.8900 (+1.14%)
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

NESS ZIONA, ISRAEL / ACCESSWIRE / November 26, 2024 / Enlivex Therapeutics Ltd. (Nasdaq:ENLV)(the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors...

ENLV : 0.8900 (+1.14%)
Enlivex Therapeutics Ltd. Approves Purchase of Up to $1 Million in Bitcoin as Part of Cash Management Strategy

Enlivex Therapeutics plans to purchase $1 million in Bitcoin to diversify its treasury reserves amid increasing demand.Quiver AI SummaryEnlivex Therapeutics Ltd., a clinical-stage company focused on macrophage...

ENLV : 0.8900 (+1.14%)
New Strong Buy Stocks for October 23rd

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Rent the Runway, Inc. RENT: This designer clothing rental company has seen the Zacks Consensus Estimate for its current year earnings...

ENLV : 0.8900 (+1.14%)
PTON : 5.75 (+8.08%)
GTEC : 1.4200 (unch)
DSGR : 25.85 (+3.07%)
RENT : 4.02 (+6.63%)
CREA Stats, U.S. Retail Sales Featured Next Week

Monday U.S. Featured Earnings Lennar Corp. (NYSE: LEN) (Q2) EPS of $3.20, compared to $2.94 ...

DLNG : 3.37 (+1.81%)
SCS : 9.62 (+2.12%)
ASTL.TO : 6.73 (-0.15%)
DDD : 1.7900 (+0.56%)
PDCO : 31.33 (+0.03%)
KR : 72.98 (+0.93%)
ET.TO : 10.57 (+1.05%)
CRMT : 48.02 (+3.45%)
KBH : 53.66 (+5.07%)
ENLV : 0.8900 (+1.14%)
LEN : 107.92 (+4.06%)
FDS : 423.96 (+2.65%)
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™

Nes-Ziona, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

ENLV : 0.8900 (+1.14%)
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

First clinical trial of Allocetra™ in patients with cancer builds upon promising preclinical studies demonstrating its broadly applicable immunotherapeutic...

ENLV : 0.8900 (+1.14%)

Business Summary

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome)...

See More

Key Turning Points

3rd Resistance Point 0.9500
2nd Resistance Point 0.9340
1st Resistance Point 0.9120
Last Price 0.8900
1st Support Level 0.8740
2nd Support Level 0.8580
3rd Support Level 0.8360

See More

52-Week High 1.8400
Fibonacci 61.8% 1.4466
Fibonacci 50% 1.3250
Fibonacci 38.2% 1.2035
Last Price 0.8900
52-Week Low 0.8101

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro